Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy (NCT06809946) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy
Netherlands20 participantsStarted 2026-08-17
Plain-language summary
In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and/or lymph nodes considered to be malignant.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Signed informed consent prior to participation in the study.
✓. Age ≥ 18 years.
✓. Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin).
✓. Patient is considered fit to undergo a diagnostic and/or therapeutic bronchoscopy (with or without addition of virtual navigation and/or endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.
Exclusion criteria
✕. History of infusion reactions to bevacizumab.
✕. Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
✕. Pregnancy or breast feeding.
What they're measuring
1
Fluorescent signal of malignant lesion versus non-tumorous tissue.
Timeframe: Assessed directly during the bronchoscopy procedure